{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T06:40:25Z","timestamp":1711694425497},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T00:00:00Z","timestamp":1281398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s00280-010-1411-0","type":"journal-article","created":{"date-parts":[[2010,8,9]],"date-time":"2010-08-09T08:45:31Z","timestamp":1281343531000},"page":"1247-1256","source":"Crossref","is-referenced-by-count":10,"title":["A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV)"],"prefix":"10.1007","volume":"67","author":[{"given":"Petr","family":"Sova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolf","family":"Mistr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ales","family":"Kroutil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Semer\u00e1d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Chlubnov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Hruskov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jirina","family":"Chl\u00e1dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslav","family":"Chl\u00e1dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,10]]},"reference":[{"key":"1411_CR1","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0959-8049(98)00224-X","volume":"34","author":"D Lebwohl","year":"1998","unstructured":"Lebwohl D, Canetta R (1998) Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34:1522\u20131534","journal-title":"Eur J Cancer"},{"key":"1411_CR2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"LR Kelland","year":"2007","unstructured":"Kelland LR (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573\u2013584","journal-title":"Nat Rev Cancer"},{"key":"1411_CR3","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-07-2176","volume":"14","author":"H Choy","year":"2008","unstructured":"Choy H, Park C, Yao M (2008) Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 14:1633\u20131638","journal-title":"Clin Cancer Res"},{"key":"1411_CR4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1021\/jm030858+","volume":"47","author":"F Zak","year":"2004","unstructured":"Zak F, Tur\u00e1nek J, Kroutil A, Sova P, Mistr A, Poulov\u00e1 A, Mikolin P, Zak Z, Kasna A, Zaluska D, Neca J, Sindlerova L, Kozubik A (2004) Platinum (IV) complex with adamantylamine as non-leaving amine group: synthesis, characterization, and in vitro antitumour activity against the panel of cisplatin resistant cancer cell lines. J Med Chem 47:761\u2013763","journal-title":"J Med Chem"},{"key":"1411_CR5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bcp.2004.09.005","volume":"69","author":"A Kozubik","year":"2005","unstructured":"Kozubik A, Horvath V, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P et al (2005) High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol 69:373\u2013383","journal-title":"Biochem Pharmacol"},{"key":"1411_CR6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00001813-200602000-00012","volume":"17","author":"P Sova","year":"2006","unstructured":"Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M (2006) Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anticancer Drugs 17:201\u2013206","journal-title":"Anticancer Drugs"},{"key":"1411_CR7","doi-asserted-by":"crossref","unstructured":"Roubalov\u00e1 E, Kvardov\u00e1 V, Hrstka R, Bo\u0159ilov\u00e1 S, Michalov\u00e1 E, Dubsk\u00e1 L, M\u00fcller P, Sova P, Vojt\u011b\u0161ek B (2009) The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. Invest New Drugs Jun 5 [Epub ahead of print]","DOI":"10.1007\/s10637-009-9270-4"},{"key":"1411_CR8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1021\/ic00109a004","volume":"34","author":"CM Giandomenico","year":"1995","unstructured":"Giandomenico CM, Abrams MJ, Murrer BA, Vollano JF, Rheinheimer MI, Wyer SB, Bossard GE, Higgins JD (1995) Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entre\u00e9 into orally active platinum(IV) antitumor agents. Inorg Chem 34:1015\u20131021","journal-title":"Inorg Chem"},{"key":"1411_CR9","first-page":"4118","volume":"54","author":"MJ McKeage","year":"1994","unstructured":"McKeage MJ, Kelland LR, Boxall FE, Valenti MR, Jones M, Goddard PM, Gwynne J, Harrap KR (1994) Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Res 54:4118\u20134122","journal-title":"Cancer Res"},{"key":"1411_CR10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00685793","volume":"36","author":"MJ McKeage","year":"1995","unstructured":"McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O\u2019Neill C, Ellis P, Kelland LR, Morgan SE, Murrer B et al (1995) A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36:451\u2013458","journal-title":"Cancer Chemother Pharmacol"},{"key":"1411_CR11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/01.cad.0000127147.57796.e5","volume":"15","author":"J Tur\u00e1nek","year":"2004","unstructured":"Tur\u00e1nek J, Kasn\u00e1 A, Z\u00e1lusk\u00e1 D, Neca J, Kvardov\u00e1 V, Kn\u00f6tigov\u00e1 P et al (2004) New platinum (IV) complex with adamantylamine ligand as a promising anticancer drug: comparison of in vitro cytotoxic potential towards A2780\/cisR cisplatin-resistant cell line within homologous series of platinum (IV) complexes. Anti-Cancer Drugs 15:537\u2013543","journal-title":"Anti-Cancer Drugs"},{"key":"1411_CR12","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1124\/mol.106.027730","volume":"70","author":"J Kasp\u00e1rkov\u00e1","year":"2006","unstructured":"Kasp\u00e1rkov\u00e1 J, Nov\u00e1kov\u00e1 O, Vr\u00e1na O, Intini F, Natile G, Brabec V (2006) Molecular aspect of antitumor effects of a new platinum(IV) drug. Mol Pharmacol 70:1708\u20131719","journal-title":"Mol Pharmacol"},{"key":"1411_CR13","first-page":"2581","volume":"53","author":"LR Kelland","year":"1993","unstructured":"Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR (1993) Preclinical antitumor evaluation of Bis-acetato-ammine-dichloro-cyclohexylamine Platinum(IV): an orally active platinum drug. Cancer Res 53:2581\u20132586","journal-title":"Cancer Res"},{"key":"1411_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jtemb.2010.01.006","volume":"24","author":"B Michalke","year":"2010","unstructured":"Michalke B (2010) Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs. J Trace Elem Med Biol 24:69\u201377","journal-title":"J Trace Elem Med Biol"},{"key":"1411_CR15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1039\/a900199i","volume":"14","author":"P Galettis","year":"1999","unstructured":"Galettis P, Carr JL, Paxton JW, McKeage MJ (1999) Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation. J Anal At Spectrom 14:953\u2013956","journal-title":"J Anal At Spectrom"},{"key":"1411_CR16","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0731-7085(95)01571-X","volume":"13","author":"GK Poon","year":"1995","unstructured":"Poon GK, Mistry P, Raynaud FI, Harrap KR, Murrer BA, Barnard CF (1995) Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates. J Pharm Biomed Anal 13:1493\u20131498","journal-title":"J Pharm Biomed Anal"},{"key":"1411_CR17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s002800050464","volume":"38","author":"FI Raynaud","year":"1996","unstructured":"Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CF, Murrer BA, Harrap KR (1996) Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 38:155\u2013162","journal-title":"Cancer Chemother Pharmacol"},{"key":"1411_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00280-002-0462-2","volume":"50","author":"JL Carr","year":"2002","unstructured":"Carr JL, Tingle MD, McKeage MJ (2002) Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother Pharmacol 50:9\u201315","journal-title":"Cancer Chemother Pharmacol"},{"key":"1411_CR19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00280-005-0069-5","volume":"57","author":"JL Carr","year":"2006","unstructured":"Carr JL, Tingle MD, McKeage MJ (2006) Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro. Cancer Chemother Pharmacol 57:483\u2013490","journal-title":"Cancer Chemother Pharmacol"},{"key":"1411_CR20","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1440-1681.2008.05017.x","volume":"35","author":"DN Bell","year":"2008","unstructured":"Bell DN, Liu JJ, Tingle MD, Rattel B, Meyer TU, McKeage MJ (2008) Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro. Clin Exp Pharmacol Physiol 35:1440\u20131446","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1411_CR21","first-page":"1857","volume":"16","author":"FI Raynaud","year":"1996","unstructured":"Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR (1996) Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Anticancer Res 16:1857\u20131862","journal-title":"Anticancer Res"},{"key":"1411_CR22","first-page":"2757","volume":"23","author":"S Vouillamoz-Lorenz","year":"2003","unstructured":"Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA (2003) Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14\u00a0days. Anticancer Res 23:2757\u20132765","journal-title":"Anticancer Res"},{"key":"1411_CR23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/jjco\/hyd102","volume":"30","author":"T Kurata","year":"2000","unstructured":"Kurata T, Tamura T, Sasaki Y, Fujii H, Negoro S, Fukuoka M, Saijo N (2000) Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 30:377\u2013384","journal-title":"Jpn J Clin Oncol"},{"key":"1411_CR24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1211\/0022357001777496","volume":"52","author":"K Hanada","year":"2000","unstructured":"Hanada K, Ninomiya K, Ogata H (2000) Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin. J Pharm Pharmacol 52:1345\u20131353","journal-title":"J Pharm Pharmacol"},{"key":"1411_CR25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijpharm.2004.09.020","volume":"288","author":"P Sova","year":"2005","unstructured":"Sova P, Chladek J, Zak F, Mistr A, Kroutil A, Semerad M, Slovak Z (2005) Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6\u201343)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV)]. Int J Pharm 288:123\u2013129","journal-title":"Int J Pharm"},{"key":"1411_CR26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s002800050736","volume":"41","author":"A Johnsson","year":"1998","unstructured":"Johnsson A, Bj\u00f6rk H, Sch\u00fctz A, Sk\u00e4rby T (1998) Sample handling for determination of free platinum in blood after cisplatin exposure. Cancer Chemother Pharmacol 41:248\u2013251","journal-title":"Cancer Chemother Pharmacol"},{"key":"1411_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0731-7085(00)00377-0","volume":"24","author":"JG Morrison","year":"2000","unstructured":"Morrison JG, White P, McDougall S, Firth JW, Woolfrey SG, Graham MA, Greenslade D (2000) Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal 24:1\u201310","journal-title":"J Pharm Biomed Anal"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1411-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1411-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1411-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T06:16:36Z","timestamp":1711692996000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1411-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,10]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["1411"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1411-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,10]]}}}